Company Filing History:
Years Active: 2018-2025
Title: Innovator Spotlight: Leonardo Resende Allain
Introduction
Leonardo Resende Allain is a notable inventor based in Lansdale, Pennsylvania, recognized for his significant contributions to the pharmaceutical industry. With a portfolio of seven patents, Allain has focused primarily on the treatment of migraines, showcasing his dedication to improving patient care and outcomes.
Latest Patents
Among his recent innovations, Allain has developed innovative pharmaceutical formulations for the treatment of migraine. His patents include methods for the acute treatment of migraine with or without aura, specifically incorporating the administration of ubrogepant. These groundbreaking methods particularly address the needs of various patient groups, including those with hepatic impairment and renal impairment, as well as patients taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors. His work marks a significant advancement in migraine therapy, providing tailored treatment options for diverse patients.
Career Highlights
Allain has made considerable strides in his career, having worked for esteemed organizations such as Merck Sharp & Dohme Corporation and Merck Sharp & Dohme Corp. His experience in these leading pharmaceutical companies has played a pivotal role in shaping his skills and expertise in drug formulation and development.
Collaborations
Throughout his career, Leonardo has collaborated with notable professionals in the industry, including Mary Ann Johnson and W Mark Eickhoff. These collaborations have undoubtedly enriched his perspective and fueled his innovation in creating effective treatments for migraine sufferers.
Conclusion
Leonardo Resende Allain exemplifies the spirit of innovation and dedication in the field of pharmaceuticals. With his impressive patent portfolio and collaborative efforts in the industry, he continues to make substantial contributions aimed at enhancing therapeutic options for migraine patients. His ongoing work is a testament to his commitment to advancing medical science for the benefit of others.